Bacil Pharma [BACPHAR] vs Sun Pharma Advanced [SPARC] Detailed Stock Comparison
Bacil Pharma
BSE
Loading...
Sun Pharma Advanced
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Bacil Pharma wins in 11 metrics, Sun Pharma Advanced wins in 6 metrics, with 0 ties. Bacil Pharma appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Bacil Pharma | Sun Pharma Advanced | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 30.00 | -13.28 | Sun Pharma Advanced |
| Price-to-Book Ratio | 1.13 | -20.93 | Sun Pharma Advanced |
| Debt-to-Equity Ratio | 0.64 | -1.24 | Sun Pharma Advanced |
| PEG Ratio | -0.03 | 0.29 | Bacil Pharma |
| EV/EBITDA | -153.41 | -16.99 | Bacil Pharma |
| Profit Margin (TTM) | 111.61% | -53.22% | Bacil Pharma |
| Operating Margin (TTM) | -10.86% | -568.05% | Bacil Pharma |
| Return on Equity | 1.59% | 157.88% | Sun Pharma Advanced |
| Return on Assets (TTM) | 1.58% | -102.08% | Bacil Pharma |
| Free Cash Flow (TTM) | $4.01M | $-3.71B | Bacil Pharma |
| 1-Year Return | 92.79% | -36.71% | Bacil Pharma |
| Price-to-Sales Ratio (TTM) | 21.92 | 70.63 | Bacil Pharma |
| Enterprise Value | $487.13M | $48.19B | Sun Pharma Advanced |
| EV/Revenue Ratio | 49.12 | 74.60 | Bacil Pharma |
| Gross Profit Margin (TTM) | N/A | -10.68% | N/A |
| Revenue per Share (TTM) | $1 | $2 | Sun Pharma Advanced |
| Earnings per Share (Diluted) | $1.23 | $-9.19 | Bacil Pharma |
| Beta (Stock Volatility) | 0.30 | 0.31 | Bacil Pharma |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Bacil Pharma vs Sun Pharma Advanced Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Bacil Pharma | -1.60% | -1.60% | -1.81% | -11.19% | -11.53% | -30.72% |
| Sun Pharma Advanced | -0.13% | -4.10% | -8.75% | -22.48% | 24.65% | -30.20% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Bacil Pharma | 92.79% | 766.20% | 1,146.62% | 476.56% | 638.00% | 246.48% |
| Sun Pharma Advanced | -36.71% | -38.11% | -20.20% | -61.55% | 51.01% | -51.80% |
Performance & Financial Health Analysis: Bacil Pharma vs Sun Pharma Advanced
| Metric | BACPHAR | SPARC |
|---|---|---|
| Market Information | ||
| Market Cap | ₹217.34M | ₹45.62B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 29,436 | 198,538 |
| 90 Day Avg. Volume | 31,562 | 271,881 |
| Last Close | ₹36.90 | ₹140.09 |
| 52 Week Range | ₹16.24 - ₹62.56 | ₹109.30 - ₹241.00 |
| % from 52W High | -41.02% | -41.87% |
| All-Time High | ₹62.56 (Dec 16, 2024) | ₹875.00 (Apr 24, 2006) |
| % from All-Time High | -41.02% | -83.99% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | -0.43% |
| Quarterly Earnings Growth | N/A | -0.43% |
| Financial Health | ||
| Profit Margin (TTM) | 1.12% | -0.53% |
| Operating Margin (TTM) | -0.11% | -5.68% |
| Return on Equity (TTM) | 0.02% | 1.58% |
| Debt to Equity (MRQ) | 0.64 | -1.24 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹32.60 | ₹-6.69 |
| Cash per Share (MRQ) | ₹2.05 | ₹0.06 |
| Operating Cash Flow (TTM) | ₹4.03M | ₹-3,484,287,000 |
| Levered Free Cash Flow (TTM) | ₹4.04M | ₹-3,425,094,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Bacil Pharma vs Sun Pharma Advanced
| Metric | BACPHAR | SPARC |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 30.00 | -13.28 |
| Forward P/E | N/A | 2.54 |
| PEG Ratio | -0.03 | 0.29 |
| Price to Sales (TTM) | 21.92 | 70.63 |
| Price to Book (MRQ) | 1.13 | -20.93 |
| Market Capitalization | ||
| Market Capitalization | ₹217.34M | ₹45.62B |
| Enterprise Value | ₹487.13M | ₹48.19B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 49.12 | 74.60 |
| Enterprise to EBITDA | -153.41 | -16.99 |
| Risk & Other Metrics | ||
| Beta | 0.30 | 0.31 |
| Book Value per Share (MRQ) | ₹32.60 | ₹-6.69 |
Financial Statements Comparison: Bacil Pharma vs Sun Pharma Advanced
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | BACPHAR | SPARC |
|---|---|---|
| Revenue/Sales | ₹0 | ₹96.40M |
| Cost of Goods Sold | N/A | ₹106.70M |
| Gross Profit | N/A | ₹-10.30M |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹-1.09M | ₹-547.60M |
| EBITDA | ₹-1.09M | ₹-429.40M |
| Pre-Tax Income | ₹8.94M | ₹-518.10M |
| Income Tax | ₹2.25M | ₹600,000 |
| Net Income (Profit) | ₹6.69M | ₹-518.70M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | BACPHAR | SPARC |
|---|---|---|
| Cash & Equivalents | ₹28.57M | ₹19.64M |
| Total Current Assets | ₹29.08M | ₹261.97M |
| Total Current Liabilities | ₹1.69M | ₹3.74B |
| Long-Term Debt | N/A | ₹1.07B |
| Total Shareholders Equity | ₹254.31M | ₹-2.17B |
| Retained Earnings | N/A | ₹-23.22B |
| Property, Plant & Equipment | N/A | ₹178.02M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | BACPHAR | SPARC |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | BACPHAR | SPARC |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 29,436 | 198,538 |
| Average Daily Volume (90 Day) | 31,562 | 271,881 |
| Shares Outstanding | 5.89M | 324.52M |
| Float Shares | 12.10M | 91.74M |
| % Held by Insiders | 0.15% | 0.73% |
| % Held by Institutions | 0.00% | 0.02% |
Dividend Analysis & Yield Comparison: Bacil Pharma vs Sun Pharma Advanced
| Metric | BACPHAR | SPARC |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |